The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

The proto-oncogene MET is aberrantly activated via overexpression or mutation in numerous cancers, making it a prime anticancer molecular target. However, the clinical success of MET-directed tyrosine kinase inhibitors (TKI) has been limited due, in part, to mutations in the MET kinase domain that c...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Res
Main Authors: Miyajima, Naoto, Tsutsumi, Shinji, Sourbier, Carole, Beebe, Kristin, Mollapour, Mehdi, Rivas, Candy, Yoshida, Soichiro, Trepel, Jane B., Huang, Ying, Tatokoro, Manabu, Shinohara, Nobuo, Nonomura, Katsuya, Neckers, Len
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7561255/
https://ncbi.nlm.nih.gov/pubmed/24121490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1156
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items